Low-level laser therapy (LLLT) — delivered through laser helmets, combs, or in-clinic devices — is one of the most heavily marketed hair loss adjunct therapies. Understanding what the evidence actually shows helps patients evaluate whether it is worth adding to their regimen.
The proposed mechanism of LLLT involves photobiomodulation — the absorption of low-power red or near-infrared light by cytochrome c oxidase in mitochondria, increasing cellular energy production and stimulating follicle activity. This is a biologically plausible mechanism with some laboratory support.
The clinical evidence is modest. Several randomised controlled trials have shown statistically significant improvements in hair density with LLLT compared to sham devices, particularly in patients with mild to moderate androgenetic alopecia. The FDA has cleared certain LLLT devices for hair loss on the basis of this evidence — though clearance does not mean proven efficacy to the same standard as drug approval.
Effect sizes in LLLT trials are consistently smaller than those seen with finasteride or minoxidil. LLLT is best considered as an adjunct that may provide modest additional benefit on top of proven primary treatments, rather than as a standalone intervention.
The practical consideration is cost and compliance. Effective in-clinic LLLT requires regular sessions. Home devices (laser helmets, laser combs) require consistent use several times per week. The evidence for home devices is weaker than for clinic-based treatment. The cost of ongoing treatment — whether clinic sessions or device purchase — should be weighed against the modest expected benefit.
Related reading
